United Therapeutics (NASDAQ:UTHR) Price Target Raised to $600.00 at Oppenheimer

United Therapeutics (NASDAQ:UTHR) had its target price hoisted by Oppenheimer from $575.00 to $600.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price target points to a potential upside of 61.04% from the company’s previous close.

UTHR has been the topic of several other reports. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Morgan Stanley downgraded United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $310.00 to $321.00 in a research report on Thursday, July 11th. Bank of America decreased their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research report on Thursday, August 1st. UBS Group lifted their target price on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, July 8th. Finally, TD Cowen lifted their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. One research analyst has rated the stock with a sell rating, three have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $368.15.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded up $11.18 during midday trading on Thursday, hitting $372.58. The company’s stock had a trading volume of 367,223 shares, compared to its average volume of 465,812. The stock has a market capitalization of $16.53 billion, a price-to-earnings ratio of 17.52, a PEG ratio of 1.27 and a beta of 0.57. The stock’s 50 day simple moving average is $354.34 and its 200 day simple moving average is $315.28. United Therapeutics has a fifty-two week low of $208.62 and a fifty-two week high of $377.03. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm’s revenue was up 22.9% compared to the same quarter last year. During the same period last year, the business posted $5.38 earnings per share. As a group, research analysts anticipate that United Therapeutics will post 24.72 earnings per share for the current year.

Insiders Place Their Bets

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $324.73, for a total transaction of $1,169,028.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $42,214.90. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CFO James Edgemond sold 7,782 shares of United Therapeutics stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $366.99, for a total value of $2,855,916.18. Following the completion of the transaction, the chief financial officer now owns 6,426 shares in the company, valued at approximately $2,358,277.74. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $324.73, for a total transaction of $1,169,028.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $42,214.90. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 107,012 shares of company stock worth $36,767,286 over the last quarter. Company insiders own 12.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of UTHR. SG Americas Securities LLC raised its position in United Therapeutics by 176.2% in the 1st quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock worth $3,288,000 after purchasing an additional 9,133 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in United Therapeutics by 19.0% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after purchasing an additional 4,100 shares during the last quarter. Comerica Bank raised its position in United Therapeutics by 5.9% in the 1st quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after purchasing an additional 9,244 shares during the last quarter. Tri Locum Partners LP bought a new position in United Therapeutics in the 2nd quarter worth approximately $15,959,000. Finally, QRG Capital Management Inc. raised its position in United Therapeutics by 12.4% in the 2nd quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after purchasing an additional 1,692 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.